Immunic, Inc., a renowned biotechnology company specializing in the development of small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in several significant investor and scientific conferences taking place in May.
Taking place from May 12th to 14th and May 21st to 22nd is the highly anticipated Bio€quity Europe 2024 conference. Immunic’s Vice President of Investor Relations and Communications, Jessica Breu, will be present at the event and will be hosting one-on-one investor meetings. The sessions will be held in San Sebastián, Spain, as well as virtually. Participants can schedule meetings by utilizing the Bio€quity conference portal or by contacting Jessica Breu directly.
Another vital conference on Immunic’s agenda is the Digestive Disease Week (DDW) 2024, which will be happening from May 18th to 21st. Franziska Buriánek, M.D., Senior Medical Director at Immunic, will present data from the company’s phase 1b clinical trial for IMU-856, an orally available small molecule modulator that targets SIRT6, a protein relevant to celiac disease. This oral presentation will be held in Washington, DC, and can be accessed on Immunic’s website under the “Events and Presentations” section.
Additionally, from May 29th to June 1st, the Consortium of Multiple Sclerosis Centers (CMSC) will host its 38th Annual Meeting. Robert J. Fox, M.D., will be presenting interim data from Immunic’s phase 2 CALLIPER trial of vidofludimus calcium (IMU-838), a nuclear receptor related 1 (Nurr1) activator, at this conference, held in Nashville, TN. The poster presentation will be available on Immunic’s website.
Lastly, the XXIII National Congress of Neurology, occurring from May 30th to June 2nd, will feature a presentation by Sonya Ivanova Hristova-Chakmakova, M.D., who will be presenting data from Immunic’s phase 2 CALLIPER trial in Bulgaria.
These conferences provide Immunic, Inc. with valuable opportunities to engage with investors, share research data, and make significant contributions to the advancement of clinical care for chronic inflammatory and autoimmune diseases. For more information about Immunic and its initiatives, visit their website at www.imux.com.
Immunic, Inc. is a leading biotechnology company focused on the development of small molecule therapies for chronic inflammatory and autoimmune diseases. In May, the company will be participating in several important conferences to engage with investors and present data from its clinical trials.
One of the conferences is Bio€quity Europe 2024, which will take place from May 12th to 14th and May 21st to 22nd. Jessica Breu, Immunic’s Vice President of Investor Relations and Communications, will be attending the event and hosting one-on-one investor meetings. The conference will be held in San Sebastián, Spain, as well as virtually. This conference provides an opportunity for Immunic to showcase its pipeline and engage with potential investors.
Another significant conference on Immunic’s agenda is the Digestive Disease Week (DDW) 2024, happening from May 18th to 21st. Dr. Franziska Buriánek, Senior Medical Director at Immunic, will be presenting data from the company’s phase 1b clinical trial for IMU-856, a small molecule modulator targeting SIRT6 for celiac disease. This oral presentation can be accessed on Immunic’s website under the “Events and Presentations” section. The participation in DDW allows Immunic to highlight its progress in developing therapies for digestive diseases.
The Consortium of Multiple Sclerosis Centers (CMSC) will host its 38th Annual Meeting from May 29th to June 1st. Dr. Robert J. Fox will be presenting interim data from Immunic’s phase 2 CALLIPER trial of vidofludimus calcium (IMU-838), an activator of the nuclear receptor related 1 (Nurr1), at this conference held in Nashville, TN. The poster presentation will be available on Immunic’s website. This presentation at CMSC showcases the company’s commitment to advancing treatments for multiple sclerosis.
Lastly, the XXIII National Congress of Neurology will occur from May 30th to June 2nd, featuring a presentation by Dr. Sonya Ivanova Hristova-Chakmakova, who will present data from Immunic’s phase 2 CALLIPER trial in Bulgaria. This presentation provides an opportunity for Immunic to share their research findings on the efficacy of their therapies in treating neurological conditions.
Overall, these conferences serve as platforms for Immunic to engage with investors, share research data, and make significant contributions to the advancement of clinical care for chronic inflammatory and autoimmune diseases.
However, amidst the opportunities presented by these conferences, there are also key challenges and controversies associated with Immunic’s work. One challenge is the competitive landscape of the biotechnology industry, with numerous companies vying to develop similar therapies. Immunic will need to demonstrate the efficacy and unique value of its small molecule therapies to stand out in the market.
Forecasting the market trends in the field of chronic inflammatory and autoimmune diseases, it is expected that the demand for new and effective therapies will continue to grow. As more research is conducted and scientific advancements are made, there is potential for increased investment and collaboration in this area.
For more information about Immunic and its initiatives, please visit their website at www.imux.com.